Published in Am J Pathol on July 01, 1998
Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia. Am J Pathol (2000) 2.61
Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice. Mol Cell Biol (2005) 2.25
Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice. Oncogene (2008) 1.61
The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ (2008) 1.61
Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol (2002) 1.24
Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma. World J Gastroenterol (2007) 1.11
Deciphering von Hippel-Lindau (VHL/Vhl)-associated pancreatic manifestations by inactivating Vhl in specific pancreatic cell populations. PLoS One (2009) 0.99
The VHL tumor suppressor: master regulator of HIF. Curr Pharm Des (2009) 0.93
Signalling properties of an HIV-encoded angiogenic peptide mimicking vascular endothelial growth factor activity. Biochem J (2001) 0.92
Developmentally arrested structures preceding cerebellar tumors in von Hippel-Lindau disease. Mod Pathol (2011) 0.84
EPAS1 mRNA in plasma from colorectal cancer patients is associated with poor outcome in advanced stages. Oncol Lett (2011) 0.82
Propranolol reduces viability and induces apoptosis in hemangioblastoma cells from von Hippel-Lindau patients. Orphanet J Rare Dis (2015) 0.81
Expression of HIF-2alpha/EPAS1 in hepatocellular carcinoma. World J Gastroenterol (2004) 0.81
Expression of the von Hippel-Lindau Tumor Suppressor Gene in Nonneoplastic and Neoplastic Lesions of the Thyroid. Endocr Pathol (2000) 0.79
Hypoxic induction of the regulator of G-protein signalling 4 gene is mediated by the hypoxia-inducible factor pathway. PLoS One (2012) 0.79
Vasotrophic regulation of age-dependent hypoxic cerebrovascular remodeling. Curr Vasc Pharmacol (2013) 0.76
Pathological and Clinical Features and Management of Central Nervous System Hemangioblastomas in von Hippel-Lindau Disease. J Kidney Cancer VHL (2014) 0.75
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A (1995) 24.77
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (1992) 18.26
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol (1996) 15.20
Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell (1996) 13.95
Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (1992) 10.10
Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev (1997) 8.51
Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Nature (1995) 8.12
High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell (1993) 7.14
A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci U S A (1997) 6.11
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A (1996) 5.69
Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev (1992) 5.50
Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem (1996) 5.15
Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science (1995) 4.93
Inhibition of transcription elongation by the VHL tumor suppressor protein. Science (1995) 4.23
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A (1996) 3.88
Oxygen(es) and the hypoxia-inducible factor-1. Biol Chem (1997) 2.81
HRF, a putative basic helix-loop-helix-PAS-domain transcription factor is closely related to hypoxia-inducible factor-1 alpha and developmentally expressed in blood vessels. Mech Dev (1997) 2.47
Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. Proc Natl Acad Sci U S A (1993) 2.32
Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer (1994) 2.24
Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res (1995) 2.23
Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Res (1997) 1.70
Vascular growth factors and receptors in capillary hemangioblastomas and hemangiopericytomas. Am J Pathol (1996) 1.25
Nucleotide sequence, chromosomal assignment and mRNA expression of mouse hypoxia-inducible factor-1 alpha. Biochem Biophys Res Commun (1996) 1.23
The role of vascular endothelial growth factor in blood vessel formation. Trends Cell Biol (1996) 1.15
Pathology, genetics and cell biology of hemangioblastomas. Histol Histopathol (1996) 1.04
Putative control of angiogenesis in hemangioblastomas by the von Hippel-Lindau tumor suppressor gene. J Neuropathol Exp Neurol (1997) 1.03
Transcriptional regulation by hypoxia-inducible factor 1 molecular mechanisms of oxygen homeostasis. Trends Cardiovasc Med (1996) 0.99
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med (2001) 6.73
Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (1994) 5.19
Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet (2001) 4.66
Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res (2000) 3.14
Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res (1996) 2.58
Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene (2000) 2.47
Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol (1998) 2.34
Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res (1995) 2.23
Up-regulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Res (1997) 1.70
Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol (1995) 1.60
KRIT1 is mutated in hyperkeratotic cutaneous capillary-venous malformation associated with cerebral capillary malformation. Hum Mol Genet (2000) 1.53
Quantitative bronchial challenge tests with wheat flour dust administered by spinhaler: comparison with aqueous wheat flour extract inhalation. J Allergy Clin Immunol (1997) 1.39
Expression of angiopoietin-1, angiopoietin-2, and tie receptors after middle cerebral artery occlusion in the rat. Am J Pathol (2000) 1.36
VEGF in brain tumors. J Neurooncol (2001) 1.33
Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. Cancer Res (1997) 1.32
LicT, a Bacillus subtilis transcriptional antiterminator protein of the BglG family. J Bacteriol (1996) 1.32
Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain (2007) 1.26
Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur J Clin Pharmacol (1998) 1.17
Cell type specific expression of vascular endothelial growth factor and angiopoietin-1 and -2 suggests an important role of astrocytes in cerebellar vascularization. Mech Dev (2001) 1.15
Evaluation of nucleolus organizer regions (NORs) by automatic image analysis: a contribution to standardization. J Pathol (1990) 1.15
Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe. Hum Genet (1996) 1.15
Synergistic stimulation of HIV-1 rev-dependent export of unspliced mRNA to the cytoplasm by hnRNP A1. J Mol Biol (1999) 1.10
Pharmacokinetics and oral bioavailability of hydrocortisone. J Clin Pharmacol (1991) 1.06
Angiogenesis in embryos and ischemic diseases. Thromb Haemost (1997) 1.05
Pathology, genetics and cell biology of hemangioblastomas. Histol Histopathol (1996) 1.04
Putative control of angiogenesis in hemangioblastomas by the von Hippel-Lindau tumor suppressor gene. J Neuropathol Exp Neurol (1997) 1.03
Interactions of INS (CRS) elements and the splicing machinery regulate the production of Rev-responsive mRNAs. J Mol Biol (1996) 1.02
Postinfectious irritable bowel syndrome: follow-up of a patient cohort of confirmed cases of bacterial infection with Salmonella or Campylobacter. Neurogastroenterol Motil (2011) 1.00
Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells. Neuropathol Appl Neurobiol (1999) 0.99
Expression and localization of placenta growth factor and PlGF receptors in human meningiomas. J Pathol (1999) 0.99
Pharmacodynamics of methylprednisolone phosphate after single intravenous administration to healthy volunteers. Pharm Res (1991) 0.97
Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants. Int J Cancer (2001) 0.96
Systemic levels contribute significantly to increased intraocular IGF-I, IGF-II and IGF-BP3 [correction of IFG-BP3] in proliferative diabetic retinopathy. Horm Metab Res (2000) 0.94
Xanthogranuloma of the sellar region. Acta Neurochir (Wien) (2005) 0.94
Dependency of cortisol suppression on the administration time of inhaled corticosteroids. J Clin Pharmacol (1997) 0.93
Determination of endogenous growth factors in human wound fluid: temporal presence and profiles of secretion. Plast Reconstr Surg (1998) 0.93
Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids. J Clin Pharmacol (1993) 0.92
A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids. J Pharmacokinet Biopharm (1999) 0.92
p53 mutations versus EGF receptor expression in giant cell glioblastomas. J Neuropathol Exp Neurol (1997) 0.92
Characterization of the androgen receptor in the skeletal muscle of the rat. Steroids (1976) 0.91
Effects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasia. Prostate (1996) 0.91
Activation of c-Jun NH2-terminal kinase/stress-activated protein kinase (JNK/SAPK) is critical for hypoxia-induced apoptosis of human malignant melanoma. Cell Growth Differ (2001) 0.91
Simultaneous measurement of cortisol in serum and saliva after different forms of cortisol administration. Clin Chem (1992) 0.90
Loss of FUBP1 expression in gliomas predicts FUBP1 mutation and is associated with oligodendroglial differentiation, IDH1 mutation and 1p/19q loss of heterozygosity. Neuropathol Appl Neurobiol (2014) 0.89
Nuclei of stroma: site of highest estrogen concentration in human benign prostatic hyperplasia. Prostate (1982) 0.89
Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. J Clin Pharmacol (2001) 0.89
Evaluation of different laboratory tests and activity indices reflecting the inflammatory activity of Crohn's disease. Scand J Gastroenterol (1992) 0.88
Vascular endothelial growth factor expression, vascular volume, and, capillary permeability in human brain tumors. Neurosurgery (1999) 0.87
Neurotoxicity, haemostatic disturbances and haemolytic anaemia after a bite by a Tunisian saw-scaled or carpet viper (Echis 'pyramidum'-complex): failure of antivenom treatment. Toxicon (1994) 0.87
A comparative study of binding, metabolism and endogenous levels of androgens in normal, hyperplastic and carcinomatous human prostate. J Steroid Biochem (1979) 0.87
Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate. J Steroid Biochem (1983) 0.86
Plasma sex hormone-binding globulin binding capacity in benign prostatic hypertrophy and prostatic carcinoma: comparison with an age dependent rise in normal human males. Acta Endocrinol (Copenh) (1977) 0.86
Evaluation of average life span of epithelial and stromal cells of human prostate by superoxide dismutase activity. Prostate (1989) 0.85
Primary culture of microvascular endothelial cells from human benign prostatic hyperplasia. Prostate (2001) 0.83
Anti-angiogenic gene therapy of malignant glioma. Acta Neurochir Suppl (1997) 0.83
Antiangiogenic gene therapy in a rat glioma model using a dominant-negative vascular endothelial growth factor receptor 2. Hum Gene Ther (1999) 0.83
Binding and metabolism of testosterone and of 5-dihydrotestosterone in bulbocavernous/levator ani (BCLA) of male rats: in vivo and in vitro studies. J Steroid Biochem (1974) 0.83
Upregulation of vascular endothelial growth factor in severe chronic brain hypoxia of the rat. Neurosci Lett (1998) 0.83
In vitro studies of testosterone and 5alpha-dihydrotestosterone binding in benign prostatic hypertrophy. Acta Endocrinol (Copenh) (1974) 0.83
Demonstration of a specific androgen receptor in rat heart muscle: relationship between binding, metabolism, and tissue levels of androgens. Endocrinology (1978) 0.82
Multicentre evaluation of an enzyme-immunoassay for cortisol determination. J Clin Chem Clin Biochem (1990) 0.82
Pharmacokinetic/pharmacodynamic evaluation of systemic effects of flunisolide after inhalation. J Clin Pharmacol (1997) 0.81
The recombinant product of the Chryptomonas phi plastid gene hlpA is an architectural HU-like protein that promotes the assembly of complex nucleoprotein structures. Eur J Biochem (1997) 0.81
Vascularization of human glioma spheroids implanted into rat cortex is conferred by two distinct mechanisms. J Neurosci Res (1999) 0.81
Gene therapy of malignant glioma: recent advances in experimental and clinical studies. Ann Oncol (1998) 0.81
Cerebellar primitive neuroectodermal tumor with multipotent differentiation in a family with von Hippel-Lindau disease. Case report. Clin Neuropathol (1993) 0.80
Binding and metabolism of 5alpha-androstane-3alpha, 17 beta-diol and of 5alpha-androstane-3beta, 17 beta-diol in the prostate, seminal vesicles and plasma of male rats: studies in vivo and in vitro. J Endocrinol (1975) 0.80
Complementary tumor induction in neural grafts exposed to N-ethyl-N-nitrosourea and an activated myc gene. Carcinogenesis (1993) 0.80
Expression of the von Hippel-Lindau-binding protein-1 (Vbp1) in fetal and adult mouse tissues. Hum Mol Genet (1999) 0.80
[Comparative quantitative clinico-chemical analysis of the characteristics of 24-hour urine and morning urine]. J Clin Chem Clin Biochem (1986) 0.79
Metabolism and mode of action of androgens in target tissues of male rats. V. Uptake and metabolism of cyproterone acetate and its influence on the uptake and metabolism of testosterone and 5alpha-dihydrotestosterone in target organs and peripheral tissues. Acta Endocrinol (Copenh) (1975) 0.79
Vascular endothelial growth factor-driven glioma growth and vascularization in an orthotopic rat model monitored by magnetic resonance imaging. Neurosurgery (2000) 0.79
Characterization of a specific androgen receptor in rat prostate cytosol by agargel electrophoresis. In vivo and in vitro studies. J Steroid Biochem (1974) 0.79
Prognostic significance of the presence of erythroblasts in blood after cardiothoracic surgery. Clin Chem Lab Med (2001) 0.79
Effect of aging on kinetic parameters of 5 alpha-reductase in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab (1988) 0.78
Kinetic analysis of androstenedione 5 alpha-reductase in epithelium and stroma of human prostate. Steroids (1998) 0.78
Inhibition of androgen metabolism in stroma and epithelium of the human benign prostatic hyperplasia by progesterone, estrone, and estradiol. Prostate (1985) 0.78
Merocyanine dyes: effect of structural modifications on photophysical properties and biological activity. Photochem Photobiol (1994) 0.78
The photophysics of merocyanine 540. A comparative study in ethanol and in liposomes. Photochem Photobiol (1988) 0.78
5 alpha-reductase inhibition by finasteride (Proscar) in epithelium and stroma of human benign prostatic hyperplasia. Steroids (1994) 0.78
Potentiation of merocyanine 540-mediated photodynamic therapy by salicylate and related drugs. Photochem Photobiol (1995) 0.78
Effects of sexual rest or sexual activity on the structure and function of the ventral prostate of the rat. Anat Rec (1985) 0.77
Inactivation of photosensitizing merocyanine dyes by plasma, serum and serum components. Photochem Photobiol (1996) 0.77
Mechanism-based PK/PD model for the lymphocytopenia induced by endogenous and exogenous corticosteroids. Int J Clin Pharmacol Ther (1999) 0.77
Lipid composition in epithelium and stroma of human benign prostatic hyperplasia. Prostate (1997) 0.77
Enzyme activities in tissue of human benign prostatic hyperplasia after three months' treatment with the Sabal serrulata extract IDS 89 (Strogen) or placebo. Eur Urol (1997) 0.77
Hormone blood levels and their inter-relationships in normal men and men with benign prostatic hyperplasia (BPH). Acta Endocrinol (Copenh) (1979) 0.77
Retrovirus producer cells encoding antisense VEGF prolong survival of rats with intracranial GS9L gliomas. Int J Dev Neurosci (1999) 0.77
Prognostic significance of low serum cholesterol after cardiothoracic surgery. Clin Chem (2000) 0.77
Making the case for adapting the abbreviated burn severity index to include erythroblast count. J Wound Care (2005) 0.77
Estimation of the mortality risk of surgical intensive care patients based on routine laboratory parameters. Eur Surg Res (2008) 0.76
Pharmacokinetics and rectal bioavailability of hydrocortisone acetate after single and multiple administration in healthy subjects and patients. J Clin Pharmacol (2001) 0.76
Androgen metabolism in patients with benign prostatic hypertrophy. Vitam Horm (1975) 0.76
In vitro metabolism of 5 alpha-dihydrotestosterone to 5 alpha-androstane-3 alpha, 17 beta-diol in rat heart, diaphragm, skeletal muscle and bulbocavernosus/levator ani: enzyme characterization and quantification. J Steroid Biochem (1980) 0.76
Comparison between the binding of 19-nortestosterone, 5alpha-dihydrotestosterone and testosterone in rat prostate and bulbocavernosus/levator ani muscle. J Endocrinol (1976) 0.76
Application of the AgNOR method to cell imprints. J Pathol (1989) 0.76